Anti-tumor action and clinical application of proteasome inhibitor

被引：1

作者：

Zhou Yong-ming ^{[2
]}

Yu Mei-xia ^{[2
]}

Long Hui ^{[2
]}

Huang Shi-ang ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Stem Cell Ctr, Wuhan 430022, Peoples R China

[2] Wuhan Univ Sci & Technol, Affiliated Hosp, Dept Hematol, Wuhan 430000, Peoples R China

来源：

CHINESE JOURNAL OF CANCER RESEARCH | 2008年 / 20卷 / 02期

关键词：

proteasome inhibitor; ubiquitin-proteasome pathway; tumor;

D O I：

10.1007/s11670-008-0077-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ubiquitin-proteasome pathway mediates the degradation of cell protein, and cell cycle, gene translation and expression, antigen presentation and inflammatory development. Proteasome inhibitor can inhibit growth and proliferation of tumor cell, induce apoptosis and reverse multipledrug resistance of tumor cell, increase the sensitivity of other chemotherapeutic drugs and radiotherapy, and is a novel class of potent anti-tumor agents.

引用

页码：77 / 84

页数：8

共 50 条

[1] Anti-tumor Action and Clinical Application of Proteasome Inhibitor
周咏明
余美霞
龙辉
黄士昂
Chinese Journal of Cancer Research, 2008, (02) : 77 - 84
[2] Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer
Nakata, Wachiko
Hayakawa, Yoku
Nakagawa, Hayato
Sakamoto, Kei
Kinoshita, Hiroto
Takahashi, Ryota
Hirata, Yoshihiro
Maeda, Shin
Koike, Kazuhiko
INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39 (06) : 1529 - 1536
[3] Anti-Tumor Activity of the Proteasome Inhibitor Bortezomib in Gastric Cancer
Nakata, Wachiko
Hayakawa, Yoku
Nakagawa, Hayato
Sakamoto, Kei
Kinoshita, Hiroto
Takahashi, Ryota
Hirata, Yoshihiro
Maeda, Shin
Koike, Kazuhiko
GASTROENTEROLOGY, 2011, 140 (05) : S674 - S674
[4] Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma
Kodera, Yuka
Iguchi, Takaaki
Kato, Daiki
Ikeda, Namiko
Shinada, Masahiro
Aoki, Susumu
Soga, Kyoka
Li, Toshio
Ohata, Ryosuke
Koseki, Shoma
Shibahara, Hayato
Takahashi, Yosuke
Hashimoto, Yuko
Nishimura, Ryohei
Nakagawa, Takayuki
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2024, 86 (09): : 961 - 965
[5] Sustained proteasome inhibition by carfilzomib, a selective proteasome inhibitor, enhances anti-tumor activity
Aujay, Monette
Demo, Susan
Jiang, Jing
Kirk, Christopher
Parlati, Francesco
Suzuki, Erika
Woo, Tina
Bennett, Mark
CANCER RESEARCH, 2009, 69
[6] Proteasome inhibitor enhance histone deacetylase inhibitor mediated anti-tumor efficacy in TSCC
Tang, H.
Wang, J.
Hou, J.
Tao, Q.
Huang, H.
ORAL ONCOLOGY, 2011, 47 : S28 - S29
[7] CLINICAL-STUDIES ON THE ANTI-TUMOR ACTION OF MECAPHANE
ZHANG, ZY
YU, LY
SUN, ZY
TANG, WY
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1981, 6 (02) : 155 - 159
[8] STUDIES ON CLINICAL APPLICATION OF ANTI-TUMOR ENZYME THERAPY
KODAMA, J
HIGASHIN.K
KOBAYASH.S
IZUMI, K
SATANI, M
TAKAMITS.Y
KAWAI, K
JAPANESE JOURNAL OF MEDICINE, 1974, 13 (02) : 115 - 117
[9] Anti-angiogenic and anti-tumor properties of proteasome inhibitors
Daniel, KG
Kuhn, DJ
Kazi, A
Dou, QP
CURRENT CANCER DRUG TARGETS, 2005, 5 (07) : 529 - 541
[10] Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma
Zang, Meirong
Li, Zengjun
Liu, Lanting
Li, Fei
Li, Xin
Dai, Yun
Li, Wei
Kuckelkorn, Ulrike
Doeppner, Thorsten R.
Hermann, Dirk M.
Zhou, Wen
Qiu, Lugui
Jin, Fengyan
CANCER LETTERS, 2015, 366 (02) : 173 - 181

← 1 2 3 4 5 →